Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma

Anti-Cancer Drugs

Volumn 15, Issue 10, 2004, Pages 955-960

  Eucker, Jan ^a   Bängeroth, Katharina ^a   Zavrski, Ivana ^a   Krebbel, Holger ^a   Zang, Chuanbing ^a   Heider, Ulrike ^a   Jakob, Christian ^a   Elstner, Elena ^a   Possinger, Kurt ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Chemotherapy; Multiple myeloma; Peroxisome proliferator activated receptor; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; LIPOCORTIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIGANDS; MULTIPLE MYELOMA; PPAR GAMMA; PROSTAGLANDIN D2; THIAZOLIDINEDIONES;

EID: 9344263462     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200411000-00004     Document Type: Article

References (31)

1. Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101:2094-2098.
2. Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003; 129:234-238.
3. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, et al. Expression of receptor activator of NF-κB ligand (RANKL) on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003; 9:1436-1440.
4. Jakob C, Zavrski I, Heider U, Bollow M, Schulz CO, Fleissner C, et al. Serum levels of carboxy-terminal telopeptide of type-l collagen (ICTP) are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003; 9:3047-3051.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
6. Dredge K, Dalgleish AG, Marriott JB. Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 2003; 14:331-335.
7. Eucker J, Eikel D, Heider U, Jakob C, Zavrski I, Gatz F, et al. Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion. Anticancer Drugs 2003; 14: 793-799.
8. Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003; 129:383-391.
9. Stead ML, Brown JM, Velikova G, Kaasa S, Wisloff F, Child JA, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol 1999; 104:605-611.
10. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-688.
11. Konopleva M, Andreeff M. Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr Opin Hematol 2002; 9:294-302.
12. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
13. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003; 9:1-9.
14. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, et al. Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74:155-165.
15. Smith MR, Kantoff PW. Peroxisome proliferator activated receptor gamma (PPARγ) as a novel target for prostate cancer. Invest New drugs 2002; 20:195-200.
16. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002; 50:563-567.
17. Asou H, Verbeek W, Williamson E, Elstner E, Kubota T, Kamada N, et al. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol 1999; 15:1027-1031.
18. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-8888.
19. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998; 4:1046-1052.
20. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-γ agonists. Clin Immunol 2002; 103:22-33.
21. 2 induce apoptosis in normal and malignant B-lineage cells. J Immunol 2000; 165:6941-6948.
22. Padilla J, Kaur K, Harris SG, Phipps RR PPAR-γ-mediated regulation of normal and malignant B lineage cells. Ann NY Acad Sci 2000; 905:97-109.
23. 2 metabolite binds peroxisome proliferator activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83:813-819.
24. Maehara Y, Anai H, Tamada R, Sugimachi K. The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol 1987; 23:273-276.
25. Zang C, Wachter M, Liu H, Posch MG, Fenner MH, Stadelmann C, et al. Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 2003; 65:107-118.
26. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ. J Neurochem 2002; 81:1052-1060.
27. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator activated receptor gamma in non-small cell lung cancer. Clin Cancer Res 2000; 60:1129-1138.
28. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100:3149-3153.
29. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175-3184.
30. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101:3126-3135.
31. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.